KR101170184B1 - 벤즈이미다졸 유도체, 그를 포함하는 조성물, 및 그의 제조방법 및 그의 용도 - Google Patents

벤즈이미다졸 유도체, 그를 포함하는 조성물, 및 그의 제조방법 및 그의 용도 Download PDF

Info

Publication number
KR101170184B1
KR101170184B1 KR1020067005825A KR20067005825A KR101170184B1 KR 101170184 B1 KR101170184 B1 KR 101170184B1 KR 1020067005825 A KR1020067005825 A KR 1020067005825A KR 20067005825 A KR20067005825 A KR 20067005825A KR 101170184 B1 KR101170184 B1 KR 101170184B1
Authority
KR
South Korea
Prior art keywords
alkyl
methyl
cycloalkyl
butyl
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020067005825A
Other languages
English (en)
Korean (ko)
Other versions
KR20070001052A (ko
Inventor
지핑 리우
다니엘 페이지
크리스토퍼 발폴
후아 양
Original Assignee
아스트라제네카 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스트라제네카 아베 filed Critical 아스트라제네카 아베
Publication of KR20070001052A publication Critical patent/KR20070001052A/ko
Application granted granted Critical
Publication of KR101170184B1 publication Critical patent/KR101170184B1/ko
Assigned to 네오메드 인스티튜트 reassignment 네오메드 인스티튜트 권리의 전부이전등록 Assignors: 아스트라제네카 아베
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020067005825A 2003-09-26 2004-09-24 벤즈이미다졸 유도체, 그를 포함하는 조성물, 및 그의 제조방법 및 그의 용도 Expired - Lifetime KR101170184B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0302573A SE0302573D0 (sv) 2003-09-26 2003-09-26 Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302573-1 2003-09-26
PCT/GB2004/004124 WO2005030732A1 (en) 2003-09-26 2004-09-24 Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof

Publications (2)

Publication Number Publication Date
KR20070001052A KR20070001052A (ko) 2007-01-03
KR101170184B1 true KR101170184B1 (ko) 2012-07-31

Family

ID=29246982

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067005825A Expired - Lifetime KR101170184B1 (ko) 2003-09-26 2004-09-24 벤즈이미다졸 유도체, 그를 포함하는 조성물, 및 그의 제조방법 및 그의 용도

Country Status (33)

Country Link
US (1) US8633235B2 (https=)
EP (1) EP1670769B1 (https=)
JP (1) JP4896721B2 (https=)
KR (1) KR101170184B1 (https=)
CN (2) CN102010373A (https=)
AR (1) AR045819A1 (https=)
AT (1) ATE430135T1 (https=)
AU (1) AU2004276062B2 (https=)
BR (1) BRPI0414780B8 (https=)
CA (1) CA2539738C (https=)
CO (1) CO5680443A2 (https=)
CY (1) CY1110332T1 (https=)
DE (1) DE602004020907D1 (https=)
DK (1) DK1670769T3 (https=)
ES (1) ES2324669T3 (https=)
HR (1) HRP20090388T1 (https=)
IL (1) IL174215A0 (https=)
IS (1) IS8422A (https=)
MX (1) MXPA06003197A (https=)
MY (1) MY140630A (https=)
NO (1) NO20061839L (https=)
NZ (1) NZ545736A (https=)
PL (1) PL1670769T3 (https=)
PT (1) PT1670769E (https=)
RU (1) RU2346938C2 (https=)
SA (1) SA04250310B1 (https=)
SE (1) SE0302573D0 (https=)
SI (1) SI1670769T1 (https=)
TW (1) TW200521117A (https=)
UA (1) UA86776C2 (https=)
UY (1) UY28536A1 (https=)
WO (1) WO2005030732A1 (https=)
ZA (3) ZA200602446B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1558252B1 (en) 2002-08-02 2007-10-10 Merck & Co., Inc. Substituted furo [2,3-b]pyridine derivatives
SE0302573D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
WO2006033631A1 (en) * 2004-09-24 2006-03-30 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof i
UA87327C2 (ru) * 2004-09-24 2009-07-10 Астразенека Аб Производные бензимидазола, композиция, которая их содержит, их получение и применение
MX2007003105A (es) 2004-09-24 2007-06-07 Aztrazeneca Ab Derivados de bencimidazol, composiciones que los contienen, sus preparaciones y sus usos i.
WO2006033630A1 (en) * 2004-09-24 2006-03-30 Astrazeneca Ab Compounds, compositions containing them, preparation thereof and uses thereof iii
MX2007005290A (es) 2004-11-02 2007-07-09 Pfizer Derivados de sulfonilbencimidazol.
CN101233098A (zh) * 2005-07-29 2008-07-30 阿斯利康(瑞典)有限公司 成对((二氟环烷基)甲基)胺的制备方法
TW200745049A (en) 2006-03-23 2007-12-16 Astrazeneca Ab New crystalline forms
TW200808769A (en) 2006-04-18 2008-02-16 Astrazeneca Ab Therapeutic compounds
US20080139846A1 (en) * 2006-09-01 2008-06-12 Astrazeneca Ab New Process 298
EP2070927A4 (en) * 2006-09-13 2010-10-13 Kyowa Hakko Kirin Co Ltd CONDENSED HETEROCYCLIC DERIVATIVE
US20110086853A1 (en) * 2009-10-08 2011-04-14 William Brown Therapeutic Compounds
RU2414899C1 (ru) * 2009-12-29 2011-03-27 Аверин Константин Михайлович Средства для лечения рассеянного склероза
RU2454234C1 (ru) * 2011-03-16 2012-06-27 Константин Михайлович Аверин Соли 1,3-диэтилбензимидазолия - иммуностимулирующие средства и фармацевтические композиции на их основе
UA119740C2 (uk) * 2012-06-13 2019-08-12 Сайтек Текнолоджи Корп. Композиції стабілізатора, що містять заміщені хроманові сполуки, і способи застосування
SI2864291T1 (sl) 2012-06-26 2017-01-31 Bayer Pharma Aktiengesellschaft N-(4-(kinolin-4-iloksi)cikloheksil(metil))(hetero)arilkarboksamidi kot antagonisti receptorja androgena, njihova izdelava in uporaba kot medicinski izdelki
JP2021515767A (ja) 2018-03-07 2021-06-24 バイエル・アクチエンゲゼルシヤフト Ｅｒｋ５阻害剤の同定及び使用
WO2020234103A1 (en) 2019-05-21 2020-11-26 Bayer Aktiengesellschaft Identification and use of kras inhibitors
CN112010789A (zh) * 2019-05-31 2020-12-01 中国科学院上海药物研究所 乙烯基磺酰胺或乙烯基酰胺类化合物及其制备方法和用途
GB202019335D0 (en) * 2020-12-08 2021-01-20 Artelo Biosciences Ltd Pharmaceutical compositions
WO2023166450A1 (ko) * 2022-03-04 2023-09-07 삼진제약주식회사 신규한 헤테로 고리 화합물 및 이를 포함하는 약학적 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002085866A1 (en) * 2001-04-20 2002-10-31 Astrazeneca Ab Novel compounds

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1604908A (en) 1965-06-24 1971-05-15 Substd benzimidazoles - with anthelmintic,fungicidal activity and some with antiviral and antibacterial activity
FR5354M (https=) 1965-09-10 1967-09-11
US5387600A (en) 1992-07-30 1995-02-07 Fuji Photo Film Co., Ltd. Treating arteriosclerosis using benzimidazole compositions
DE4237617A1 (de) * 1992-11-06 1994-05-11 Bayer Ag Verwendung von substituierten Benzimidazolen
DE4237597A1 (de) 1992-11-06 1994-05-11 Bayer Ag Substituierte Benzimidazole
DE4237557A1 (de) 1992-11-06 1994-05-11 Bayer Ag Substituierte Benzimidazole
AU722514B2 (en) 1995-12-28 2000-08-03 Fujisawa Pharmaceutical Co., Ltd. Benzimidazole derivatives
TW453999B (en) * 1997-06-27 2001-09-11 Fujisawa Pharmaceutical Co Benzimidazole derivatives
US6348032B1 (en) * 1998-11-23 2002-02-19 Cell Pathways, Inc. Method of inhibiting neoplastic cells with benzimidazole derivatives
AU6762400A (en) 1999-08-12 2001-03-13 Cor Therapeutics, Inc. Inhibitors of factor xa
US6844367B1 (en) * 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
US6632815B2 (en) * 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US6720317B1 (en) * 1999-09-17 2004-04-13 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
JP2003509412A (ja) 1999-09-17 2003-03-11 シーオーアール セラピューティクス インコーポレイテッド Ｘａ因子阻害剤
SK287527B6 (sk) * 2000-01-14 2011-01-04 Bayer Schering Pharma Aktiengesellschaft 1,2-Diarylbenzimidazoly a ich farmaceutické použitie
US7115645B2 (en) * 2000-01-14 2006-10-03 Schering Aktiengesellschaft 1,2 diarylbenzimidazoles and their pharmaceutical use
US7329679B2 (en) * 2000-01-27 2008-02-12 Schering Aktiengesellschaft 1,2 Diarylbenzimidazoles and their pharmaceutical use
AU2001250783A1 (en) * 2000-02-29 2001-09-12 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
WO2002000651A2 (en) 2000-06-27 2002-01-03 Bristol-Myers Squibb Pharma Company Factor xa inhibitors
US20070004713A1 (en) 2000-12-07 2007-01-04 Bernard Barlaam Therapeutic benimidazole compounds
JPWO2002100833A1 (ja) 2001-06-12 2004-09-24 住友製薬株式会社 Ｒｈｏキナーゼ阻害剤
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
SE0301699D0 (sv) 2003-06-10 2003-06-10 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0301701D0 (sv) 2003-06-10 2003-06-10 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
US20050026968A1 (en) 2003-07-14 2005-02-03 University Of Tennessee Research Foundation Heterocyclic amides with anti-tuberculosis activity
WO2005021547A2 (en) 2003-08-28 2005-03-10 Pharmaxis Pty Ltd. Heterocyclic cannabinoid cb2 receptor antagonists
SE0302572D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302573D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302571D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302570D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
CA2567343A1 (en) 2004-05-20 2005-12-01 Elan Pharmaceuticals, Inc. N-cyclic sulfonamido inhibitors of gamma secretase
EP1765332A2 (en) 2004-06-17 2007-03-28 Cengent Therapeutics, Inc. Trisubstituted nitrogen modulators of tyrosine phosphatases
SG155188A1 (en) 2004-07-30 2009-09-30 Exelixis Inc Pyrrole derivatives as pharmaceutical agents
US20060052421A1 (en) * 2004-09-09 2006-03-09 Eastman Kodak Company Conjugation agent
WO2006033629A1 (en) 2004-09-24 2006-03-30 Astrazeneca Ab Benzimidazole derivatives and their use as cannabinoid receptor ligands
EP1797076A1 (en) 2004-09-24 2007-06-20 AstraZeneca AB Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
MX2007003105A (es) * 2004-09-24 2007-06-07 Aztrazeneca Ab Derivados de bencimidazol, composiciones que los contienen, sus preparaciones y sus usos i.
WO2006033632A1 (en) 2004-09-24 2006-03-30 Astrazeneca Ab Benzimidazole derivatives and their use as cannabinoid receptor ligands I
WO2006033630A1 (en) 2004-09-24 2006-03-30 Astrazeneca Ab Compounds, compositions containing them, preparation thereof and uses thereof iii
WO2006033631A1 (en) 2004-09-24 2006-03-30 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof i
EP1797070A1 (en) 2004-09-24 2007-06-20 AstraZeneca AB Compounds, compositions containing them, preparations thereof and uses thereof ii
WO2006033627A1 (en) 2004-09-24 2006-03-30 Astrazeneca Ab Compounds, compositions containing them, preparation thereof and uses thereof iiii
MX2007005290A (es) * 2004-11-02 2007-07-09 Pfizer Derivados de sulfonilbencimidazol.
WO2006078941A2 (en) 2005-01-20 2006-07-27 Sirtris Pharmaceuticals, Inc. Novel sirtuin activating compounds and methods of use thereof
TW200745049A (en) * 2006-03-23 2007-12-16 Astrazeneca Ab New crystalline forms
TW200808769A (en) * 2006-04-18 2008-02-16 Astrazeneca Ab Therapeutic compounds
TW200808772A (en) * 2006-06-13 2008-02-16 Astrazeneca Ab Therapeutic compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002085866A1 (en) * 2001-04-20 2002-10-31 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
UY28536A1 (es) 2005-04-29
ZA200702131B (en) 2008-08-27
SE0302573D0 (sv) 2003-09-26
ZA200702226B (en) 2009-01-28
CA2539738A1 (en) 2005-04-07
DK1670769T3 (da) 2009-08-10
SI1670769T1 (sl) 2009-10-31
PT1670769E (pt) 2009-07-09
MY140630A (en) 2010-01-15
SA04250310B1 (ar) 2009-01-19
HRP20090388T1 (hr) 2009-08-31
ATE430135T1 (de) 2009-05-15
CN102010373A (zh) 2011-04-13
AU2004276062A1 (en) 2005-04-07
JP4896721B2 (ja) 2012-03-14
CO5680443A2 (es) 2006-09-29
CN1886379A (zh) 2006-12-27
ES2324669T3 (es) 2009-08-12
MXPA06003197A (es) 2006-06-23
US20080207612A1 (en) 2008-08-28
TW200521117A (en) 2005-07-01
BRPI0414780B1 (pt) 2018-10-23
AR045819A1 (es) 2005-11-16
BRPI0414780B8 (pt) 2021-05-25
RU2006113371A (ru) 2007-11-10
ZA200602446B (en) 2007-09-26
PL1670769T3 (pl) 2009-09-30
BRPI0414780A (pt) 2006-11-21
AU2004276062B2 (en) 2008-05-22
KR20070001052A (ko) 2007-01-03
US8633235B2 (en) 2014-01-21
NO20061839L (no) 2006-06-26
IL174215A0 (en) 2006-08-01
EP1670769B1 (en) 2009-04-29
CA2539738C (en) 2011-11-22
UA86776C2 (ru) 2009-05-25
DE602004020907D1 (de) 2009-06-10
WO2005030732A1 (en) 2005-04-07
HK1089436A1 (en) 2006-12-01
RU2346938C2 (ru) 2009-02-20
NZ545736A (en) 2009-11-27
EP1670769A1 (en) 2006-06-21
JP2007506721A (ja) 2007-03-22
CY1110332T1 (el) 2015-01-14
IS8422A (is) 2006-04-21

Similar Documents

Publication Publication Date Title
KR101170184B1 (ko) 벤즈이미다졸 유도체, 그를 포함하는 조성물, 및 그의 제조방법 및 그의 용도
US20090111865A1 (en) Benzimidazole Derivatives, Compositions Containing Them, Preparation Thereof and Uses Thereof
JP2008519833A (ja) インダゾールスルホンアミド誘導体
US7517898B2 (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
KR20050049551A (ko) 신규 화합물
US7244850B2 (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
JP2007522209A (ja) ピロロキノリン誘導体及びピペリドキノリン誘導体、それらの製造、それらを含有する組成物及びそれらの使用
US20070265325A1 (en) Nitro Indazole Derivatives
JP2006514617A (ja) 疼痛または胃腸障害の治療のためのフェニル−ピペリジン−４−イリデン−メチル−ベンズアミド誘導体
MXPA05013052A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
HK1089436B (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20060324

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20090924

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20110527

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20120428

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20120725

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20120725

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20150717

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20150717

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20170721

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20170721

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20200715

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20210714

Start annual number: 10

End annual number: 10

PC1801 Expiration of term

Termination date: 20250324

Termination category: Expiration of duration